Conference Coverage

High CV risk factor burden in young adults a ‘smoldering’ crisis


 

FROM ACC 2023

New data show a high and rising burden of most cardiovascular (CV) risk factors among young adults aged 20-44 years in the United States.

In this age group, over the past 10 years, there has been an increase in the prevalence of diabetes and obesity, no improvement in the prevalence of hypertension, and a decrease in the prevalence of hyperlipidemia.

Yet medical treatment rates for CV risk factors are “surprisingly” low among young adults, study investigator Rishi Wadhera, MD, with Beth Israel Deaconess Medical Center and Harvard Medical School, both in Boston, told this news organization.

Dr. Rishi Wadhera of Beth Israel Deaconess Medical Center in Boston

Dr. Rishi Wadhera

The findings are “extremely concerning. We’re witnessing a smoldering public health crisis. The onset of these risk factors earlier in life is associated with a higher lifetime risk of heart disease and potentially life-threatening,” Dr. Wadhera added.

The study was presented March 5 at the joint scientific sessions of the American College of Cardiology and the World Heart Federation and was simultaneously published in JAMA.

The burden of CV risk factors among young adults is “unacceptably high and increasing,” write the co-authors of a JAMA editorial.

“The time is now for aggressive preventive measures in young adults. Without immediate action there will continue to be a rise in heart disease and the burden it places on patients, families, and communities,” say Norrina Allen, PhD, and John Wilkins, MD, with Northwestern University, Chicago.

Preventing a tsunami of heart disease

The findings stem from a cross-sectional study of 12,294 U.S. adults aged 20-44 years (mean age, 32; 51% women) who participated in National Health and Nutrition Examination Survey (NHANES) cycles for 2009-2010 to 2017-2020.

Overall, the prevalence of hypertension was 9.3% in 2009-2010 and increased to 11.5% in 2017-2020. The prevalence of diabetes rose from 3.0% to 4.1%, and the prevalence of obesity rose from 32.7% to 40.9%. The prevalence of hyperlipidemia decreased from 40.5% to 36.1%.

Black adults consistently had high rates of hypertension during the study period – 16.2% in 2009-2010 and 20.1% in 2017-2020 – and significant increases in hypertension occurred among Mexican American adults (from 6.5% to 9.5%) and other Hispanic adults (from 4.4% to 10.5%), while Mexican American adults had a significant uptick in diabetes (from 4.3% to 7.5%).

Equally concerning, said Dr. Wadhera, is the fact that only about 55% of young adults with hypertension were receiving antihypertensive medication, and just 1 in 2 young adults with diabetes were receiving treatment. “These low rates were driven, in part, by many young adults not being aware of their diagnosis,” he noted.

The NHANES data also show that the percentage of young adults who were treated for hypertension and who achieved blood pressure control did not change significantly over the study period (65.0% in 2009-2010 and 74.8% in 2017-2020). Blood sugar control among young adults being treated for diabetes remained suboptimal throughout the study period (45.5% in 2009-2010 and 56.6% in 2017-2020).

“The fact that blood pressure control and glycemic control are so poor is really worrisome,” Jeffrey Berger, MD, director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart, who wasn’t involved in the study, told this news organization.

Jeffrey S. Berger, MD, cardiologist, New York Univesrity, and director of NYU Langone's Center for the Prevention of Cardiovascular Disease NYU Langone

Dr. Jeffrey S. Berger

“Even in the lipid control, while it did get a little bit better, it’s still only around 30%-40%. So, I think we have ways to go as a society,” Dr. Berger noted.

Pages

Recommended Reading

Persistent gaps in drug use by patients with type 2 diabetes
MDedge Cardiology
Keto for life? Reasons to think twice
MDedge Cardiology
Meta-analysis throws more shade aspirin’s way
MDedge Cardiology
New ACC, AHA, SCAI interventional cardiology training guidance
MDedge Cardiology
New AHA statement urges focus on CV risk before pregnancy
MDedge Cardiology
Bempedoic acid cuts CV events in statin-intolerant patients: CLEAR Outcomes
MDedge Cardiology
NUDGE-FLU: Electronic ‘nudges’ boost flu shot uptake in seniors
MDedge Cardiology
Causal AI quantifies CV risk, providing patient-specific goals
MDedge Cardiology
COORDINATEd effort boosts optimal therapy in patients with T2D and ASCVD
MDedge Cardiology
Biomarkers linked to elevated T2D MACE risk in DECLARE-TIMI 58
MDedge Cardiology